The global MRI contrast media agents market size was estimated at USD 2.39 billion in 2025 and is projected to reach USD 4.33 billion by 2033, growing at a CAGR of 7.15% from 2026 to 2033. The market is primarily driven by the rising prevalence of chronic diseases such as cancer, neurological disorders, and cardiovascular conditions, which require advanced imaging for accurate diagnosis.
The increasing adoption of MRI procedures, driven by their non-invasive nature and superior soft-tissue visualization, is further boosting demand. In addition, ongoing technological advancements in contrast agents, including safer and more targeted formulations, are supporting market growth.
The rising global burden of chronic diseases such as cancer, neurological disorders, and cardiovascular conditions are significantly increasing the demand for accurate and early diagnostic imaging. MRI procedures, particularly those using contrast agents, play a critical role in detecting tumors, assessing brain abnormalities, and evaluating vascular conditions with high precision. As disease prevalence grows, the need for repeated imaging for diagnosis, staging, and treatment monitoring further drives the utilization of contrast-enhanced MRI. This trend is directly contributing to the sustained expansion of the MRI contrast media agents market.
Neurological disorders are a leading cause of disability and reduced quality of life worldwide.
Around 11 million deaths each year are attributed to neurological conditions.
The number of people living with dementia is projected to reach 78 million by 2030 and 139 million by 2050.
The burden of brain-related disorders exceeds that of cancer and cardiovascular diseases combined.
Technological advancements in contrast agents are significantly driving the MRI contrast media market by improving both safety and diagnostic precision. The development of macrocyclic gadolinium-based agents and emerging non-gadolinium alternatives is addressing concerns about toxicity and retention, thereby encouraging wider clinical adoption. These innovations are enhancing image clarity and enabling more accurate detection of complex conditions, supporting increased utilization of contrast-enhanced MRI. For instance, in February 2026, a review published on NCBI highlighted that advancements in MRI contrast agents are centered on high-relaxivity gadolinium-based agents (e.g., gadopiclenol, gadoquatrane), manganese-based agents, and iron oxide nanoparticles, which improve imaging performance and safety profiles. These innovations, along with the development of targeted and next-generation contrast formulations, are enhancing diagnostic precision and expanding clinical applications, thereby driving growth in the MRI contrast media agents market.
Furthermore, in April 2026, GE HealthCare announced the initiation of its global Phase 2/3 LUMINA trial, with the first patient dosed for the manganese-based MRI contrast agent mangaciclanol at Mayo Clinic. The investigational agent, granted Fast Track designation by the U.S. Food and Drug Administration, is being evaluated as a potential alternative to gadolinium-based agents for detecting lesions across the central nervous system and whole-body imaging in adult and pediatric patients.
Dr. Jit Saini, Chief Medical Officer, Pharmaceutical Diagnostics, GE HealthCare, said, “Existing gadolinium-based contrast agents carry safety language associated with gadolinium retention. In comparison, mangaciclanol could offer an alternative for broad patient groups, including vulnerable patients and those requiring multiple scans, while still offering similar diagnostic performance. The FDA Fast Track designation recognizes the potential significance of mangaciclanol and aligns with our focus on advancing its development for patients.”
“As demand for diagnostic imaging continues to rise, we continue to advance our imaging agent pipeline to better meet the needs of patients,” said Peter Arduini, President and CEO, GE HealthCare. “This clinical milestone builds on GE HealthCare’s leadership in contrast media, as mangaciclanol has the potential to transform the MR imaging market and strengthen the resiliency of its supply chain.”
Moreover, growth in advanced diagnostic imaging is another driver of the MRI contrast media/agents market, as the installation of high-field MRI systems and the expansion of radiology networks increase scan volumes. Enhanced imaging capabilities and a shift toward non-invasive, high-resolution diagnostics are encouraging greater use of contrast-enhanced MRI. This trend is particularly strong in emerging markets, where improving healthcare infrastructure is accelerating access to advanced imaging services.
The increasing adoption of MRI procedures, driven by their non-invasive nature and superior soft-tissue visualization, is further boosting demand. In addition, ongoing technological advancements in contrast agents, including safer and more targeted formulations, are supporting market growth.
The rising global burden of chronic diseases such as cancer, neurological disorders, and cardiovascular conditions are significantly increasing the demand for accurate and early diagnostic imaging. MRI procedures, particularly those using contrast agents, play a critical role in detecting tumors, assessing brain abnormalities, and evaluating vascular conditions with high precision. As disease prevalence grows, the need for repeated imaging for diagnosis, staging, and treatment monitoring further drives the utilization of contrast-enhanced MRI. This trend is directly contributing to the sustained expansion of the MRI contrast media agents market.
Rising Global Burden of Neurological Disorders
More than one in three people globally are expected to experience a neurological or psychiatric disorder during their lifetime, affecting approximately 3.4 billion individuals.Neurological disorders are a leading cause of disability and reduced quality of life worldwide.
Around 11 million deaths each year are attributed to neurological conditions.
The number of people living with dementia is projected to reach 78 million by 2030 and 139 million by 2050.
The burden of brain-related disorders exceeds that of cancer and cardiovascular diseases combined.
Technological advancements in contrast agents are significantly driving the MRI contrast media market by improving both safety and diagnostic precision. The development of macrocyclic gadolinium-based agents and emerging non-gadolinium alternatives is addressing concerns about toxicity and retention, thereby encouraging wider clinical adoption. These innovations are enhancing image clarity and enabling more accurate detection of complex conditions, supporting increased utilization of contrast-enhanced MRI. For instance, in February 2026, a review published on NCBI highlighted that advancements in MRI contrast agents are centered on high-relaxivity gadolinium-based agents (e.g., gadopiclenol, gadoquatrane), manganese-based agents, and iron oxide nanoparticles, which improve imaging performance and safety profiles. These innovations, along with the development of targeted and next-generation contrast formulations, are enhancing diagnostic precision and expanding clinical applications, thereby driving growth in the MRI contrast media agents market.
Furthermore, in April 2026, GE HealthCare announced the initiation of its global Phase 2/3 LUMINA trial, with the first patient dosed for the manganese-based MRI contrast agent mangaciclanol at Mayo Clinic. The investigational agent, granted Fast Track designation by the U.S. Food and Drug Administration, is being evaluated as a potential alternative to gadolinium-based agents for detecting lesions across the central nervous system and whole-body imaging in adult and pediatric patients.
Dr. Jit Saini, Chief Medical Officer, Pharmaceutical Diagnostics, GE HealthCare, said, “Existing gadolinium-based contrast agents carry safety language associated with gadolinium retention. In comparison, mangaciclanol could offer an alternative for broad patient groups, including vulnerable patients and those requiring multiple scans, while still offering similar diagnostic performance. The FDA Fast Track designation recognizes the potential significance of mangaciclanol and aligns with our focus on advancing its development for patients.”
“As demand for diagnostic imaging continues to rise, we continue to advance our imaging agent pipeline to better meet the needs of patients,” said Peter Arduini, President and CEO, GE HealthCare. “This clinical milestone builds on GE HealthCare’s leadership in contrast media, as mangaciclanol has the potential to transform the MR imaging market and strengthen the resiliency of its supply chain.”
Moreover, growth in advanced diagnostic imaging is another driver of the MRI contrast media/agents market, as the installation of high-field MRI systems and the expansion of radiology networks increase scan volumes. Enhanced imaging capabilities and a shift toward non-invasive, high-resolution diagnostics are encouraging greater use of contrast-enhanced MRI. This trend is particularly strong in emerging markets, where improving healthcare infrastructure is accelerating access to advanced imaging services.
Global MRI Contrast Media Agents Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, the analyst has segmented the global MRI contrast media agents market report on the basis of product, type, application, end-use, and region:Product Outlook (Revenue, USD Million, 2021-2033)
- Paramagnetic Agents
- Superparamagnetic Agents
Type Outlook (Revenue, USD Million, 2021-2033)
- Clinical
- Preclinical
Application Outlook (Revenue, USD Million, 2021-2033)
- Gastrointestinal
- Intravenous
- Hepatobiliary
- Neurological Imaging
- Others
End-use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals
- Imaging Centers
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. MRI Contrast Media Agents Market Variables, Trends, & Scope
Chapter 4. MRI Contrast Media Agents Market: Product Estimates & Trend Analysis
Chapter 5. MRI Contrast Media Agents Market: Type Estimates & Trend Analysis
Chapter 6. MRI Contrast Media Agents Market: Application Estimates & Trend Analysis
Chapter 7. MRI Contrast Media Agents Market: End Use Estimates & Trend Analysis
Chapter 8. MRI Contrast Media Agents Market: Regional Estimates & Trend Analysis by Product, Type, Application , and End Use
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- GE Healthcare
- Bayer AG
- Guerbet GmbH
- Bracco Imaging Spa
- Vitalquan, LLC
- Miltenyi Biotec B.V. & Co. Kg
- Beijing Beilu Pharmaceutical Co., Ltd.
- JB Pharma
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | May 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 2.39 Billion |
| Forecasted Market Value ( USD | $ 4.33 Billion |
| Compound Annual Growth Rate | 7.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
